細胞名稱

人急性髓系白血病細胞MUTZ-3

貨物編碼

BFN60808560

產品規格

T25培養瓶x1

1.5ml凍存管x2

細胞數量

1x10^6

1x10^6

保存溫度

37℃

-198℃

運輸方式

常溫保溫運輸

干冰運輸

安全等級

1

用途限制

僅供科研      2類

培養體系

DMEM高糖+10%FBS+1%三抗

培養溫度

37℃

二氧化碳濃度

5%

簡介

人急性髓系白血病細胞MUTZ-3取自29歲男性病人外周血。該細胞源于DSMZ。

注釋

Part of: Cancer Cell Line Encyclopedia (CCLE) project.

Part of: LL-100 blood cancer cell line panel.

Characteristics: Contains both CD34+ stem cell and CD14+ monocyte/macrophage cell populations and can thus be considered as a hematopoietic progenitor/stem cell line.

Doubling time: ~110 hours (DSMZ); 90-110 hours, in presence of supernatant of 5637 (CVCL_0126) cells (PubMed=8667638).

Omics: Deep exome analysis.

Omics: Deep RNAseq analysis.

Omics: H3K79me1 ChIP-seq epigenome analysis.

Omics: Transcriptome analysis.

Derived from sampling site: Peripheral blood.

基因突變

KRAS p.Gly10_Ala11insGly (c.31_32insGAG) (CCLE).

HLA信息

/

STR信息

Amelogenin        X,Y

CSF1PO        12,13

D5S818        12,13

D7S820        10,12

D13S317        8,12

D16S539        12

TH01        6,9.3

TPOX        8,11

vWA        14,16

參考文獻

Patent=US8455253

Goletz S., Scheper R.J., Masterson A.J., Pinedo H.M.

Differentiation of MUTZ-3 cells to produce effective dendritic cells.

Patent number US8455253, 04-Jun-2013

PubMed=30285677; DOI=10.1186/s12885-018-4840-5

Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X., Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H., Koeffler H.P.

Profiling the B/T cell receptor repertoire of lymphocyte derived cell lines.

BMC Cancer 18:940-940(2018)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3

Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Nature 569:503-508(2019)

PubMed=31160637; DOI=10.1038/s41598-019-44491-x

Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M., MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.

The LL-100 panel: 100 cell lines for blood cancer studies.

Sci. Rep. 9:8218-8218(2019)